Literature DB >> 7631260

[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].

W Wagner1, M von Eiff, F Klinke, O Micke, C Rübe, N Willich.   

Abstract

PURPOSE: In the last years new encouraging methods in the therapy of bronchial carcinoma have been elaborated. The early stages of bronchial carcinoma are still a domain of operative treatment. The long-term results of surgical treatment for locally advanced disease are considered to be unfavourable. Multimodal treatment concepts with simultaneous or consecutive application of radio-chemotherapy followed by surgical resection seem to reveal improved possibilities of therapy. PATIENTS AND METHODS: General treatment consists of 2 blocks of neoadjuvant chemotherapy with carboplatin, ifosfamide and etoposide, followed by a third course, consisting of carboplatin and vindesine. Simultaneously with the third course a hyperfractionated, accelerated radiotherapy with a single dose of 1.5 Gy 10 times per week is applied. The total dose is 45 Gy in 3 weeks, given at least to the 80% isodose. After restaging, tumor resection is carried out. Patients without tumor are randomized for prophylactic brain irradiation.
RESULTS: From January 1992 up to 1.10.1993 25 patients have been treated in accordance to the study. All tumors were locally advanced (stage IIIa and IIIb). Until 1.10.1993 4 patients died, 2 of them certainly related to the tumor. Thirteen patients have been resected after neoadjuvant treatment. In 11 of these cases a R0-, and in 2 cases a R1 resection has been carried out. Tumor cells have been found only in 5 histologies. The hematotoxic side effects under competing RTX/CTX seemed to be unproblematical (RTOG/grade II). Problems occurred with 4 cases of serious esophagitis (RTOG/grade III to IV) and 2 cases of pneumonitis with 1 case ending lethally.
CONCLUSION: Preliminary results of our study show the feasibility of multimodal treatment. A favourable 1-year survival rate after aggressive multimodal therapy and a high resection rate in previously unresectable patients could be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631260

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  3 in total

Review 1.  Regional chemotherapy of the lung: transpulmonary chemoembolization in malignant lung tumors.

Authors:  Thomas J Vogl; Mohammad Shafinaderi; Stefan Zangos; Sebastian Lindemayr; Khashayar Vatankhah
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

2.  [Treatment of stage IIIB loco-regionally advanced non-small-cell bronchial carcinomas with radiation and interferon-beta. Preliminary results of a phase II study].

Authors:  J Bund; K Eberhardt; W Hartmann; H J Habermalz
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

3.  Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases.

Authors:  Thomas J Vogl; Thomas Lehnert; Stephan Zangos; Katrin Eichler; Renate Hammerstingl; Huedayi Korkusuz; Sebastian Lindemayr
Journal:  Eur Radiol       Date:  2008-06-14       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.